---
title: "FibroBiologics (FBLG) news: reverse split and delisting"
url: "https://aibio.space/companies/fibrobiologics/"
publisher: "aibio.space (Biotech Investor Relations News)"
summary: "FBLG reverse split, delisting, convertible notes and Nasdaq notice news: FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price…"
---

FBLG FibroBiologics, Inc. NASDAQ · United States

# FibroBiologics (FBLG) news FBLG reverse split, delisting and convertible notes news

Debt Financing · 2026-10-07

## [FibroBiologics sells $1,200,000 convertible debenture to Peak One](https://aibio.space/news/fibrobiologics-sells-1-200-000-convertible-debenture-peak-one/)

FibroBiologics sold a $1,200,000 convertible debenture to Peak One Opportunity Fund, L.P. for $1,020,000, an original issue discount of 15%. The debenture matures October 8, 2027 and converts only after a default, at $0.78 per share.

## Latest FibroBiologics news

1. 2026-07-24 Listings [FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal](https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-determination-1-00-minimum-bid/) Nasdaq staff says the bid price closed below $1.00 for 30 consecutive business days and that FibroBiologics gets no 180-day compliance period after a reverse stock split. The company intends to request a hearing.
2. 2026-01-02 Listings [FibroBiologics gets Nasdaq delisting notice over bid price, plans to request a hearing](https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-notice-bid-price-plans-request/) Nasdaq staff plans to delist FibroBiologics after its stock did not regain the $1.00 minimum bid price by December 29, 2025. The company will ask for a hearing and has asked stockholders to approve a reverse split of 1 for 5 to 1 for 30.
3. 2025-08-08 Listings [FibroBiologics gets Nasdaq notice for market value below $35.0 million](https://aibio.space/news/fibrobiologics-gets-nasdaq-notice-market-value-below-35-0-million/) FibroBiologics received a Nasdaq notice that its market value of listed securities is below the $35.0 million minimum. It has until February 2, 2026 to close at or above that level for ten business days, and the 8-K gives no current market value or remedy.

## FibroBiologics at a glance

- **Ticker**: FBLG

- **Listing**: NASDAQ

- **Country**: United States

- **Cash, Jun 30, 2026**: $3.5 million

### Related companies

- [OSR Health](https://aibio.space/companies/osr-health/) OTC: OSRH
- [Janux Therapeutics](https://aibio.space/companies/janux-therapeutics/) NASDAQ: JANX
- [MindWalk Holdings](https://aibio.space/companies/mindwalk/) NASDAQ: HYFT
- [Alaunos Therapeutics](https://aibio.space/companies/alaunos-therapeutics/) NASDAQ: TCRT
- [Fennec Pharmaceuticals](https://aibio.space/companies/fennec-pharmaceuticals/) NASDAQ: FENC
- [ALX Oncology Holdings](https://aibio.space/companies/alx-oncology/) NASDAQ: ALXO
- [Nkarta](https://aibio.space/companies/nkarta/) NASDAQ: NKTX
- [Neurogene](https://aibio.space/companies/neurogene/) NASDAQ: NGNE

### Also on NASDAQ

- [Mirum Pharmaceuticals](https://aibio.space/companies/mirum-pharmaceuticals/) MIRM
- [Seres Therapeutics](https://aibio.space/companies/seres-therapeutics/) MCRB
- [Kamada](https://aibio.space/companies/kamada/) KMDA
- [Nuwellis](https://aibio.space/companies/nuwellis/) NUWE
- [60 Degrees Pharmaceuticals](https://aibio.space/companies/60-degrees-pharmaceuticals/) SXTP
- [Innoviva](https://aibio.space/companies/innoviva/) INVA

## FibroBiologics annual financials

| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | [$7.4 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) | [$4.5 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) |
| Net income (loss) | [-$18.6 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) | [-$11.2 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) |
| Cash from operations | [-$16.4 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) | [-$11.9 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) |
| Cash and equivalents | [$4.9 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526328454/) | [$14.0 million](https://www.sec.gov/Archives/edgar/data/1958777/000119312526066965/) |

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $3.5 million.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

## Questions about FibroBiologics

Did FibroBiologics do a reverse stock split?

Our latest story on this, dated Jul 24, 2026: "FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-determination-1-00-minimum-bid/).

Was FibroBiologics delisted?

Our latest story on this, dated Jul 24, 2026: "FibroBiologics gets Nasdaq delisting determination over $1.00 minimum bid price, plans appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fibrobiologics-gets-nasdaq-delisting-determination-1-00-minimum-bid/).

Has FibroBiologics sold convertible notes?

Our latest story on this, dated Oct 7, 2026: "FibroBiologics sells $1,200,000 convertible debenture to Peak One". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fibrobiologics-sells-1-200-000-convertible-debenture-peak-one/).

Has FibroBiologics received a Nasdaq deficiency notice?

Our latest story on this, dated Aug 8, 2025: "FibroBiologics gets Nasdaq notice for market value below $35.0 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/fibrobiologics-gets-nasdaq-notice-market-value-below-35-0-million/).

What is the ticker symbol of FibroBiologics?

FibroBiologics, Inc. trades under the ticker FBLG on NASDAQ.

Where is FibroBiologics listed?

FibroBiologics, Inc. is listed on NASDAQ.

What is the SEC CIK of FibroBiologics?

The SEC Central Index Key (CIK) for FibroBiologics, Inc. is 1958777. Its filings are on SEC EDGAR.

How many shares does FibroBiologics have outstanding?

6,658,193 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-07-31.

Which country or territory is FibroBiologics listed under?

Our directory records FibroBiologics, Inc. under United States.

What does FibroBiologics do?

Our directory classifies FibroBiologics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.

What is the ISIN of FibroBiologics?

The ISIN recorded for FibroBiologics, Inc. is US31573L2043.

Does aibio.space cover FibroBiologics?

aibio.space lists FibroBiologics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

Where is FibroBiologics incorporated?

SEC records list its state or country of incorporation as DE.

Is FibroBiologics profitable?

FibroBiologics, Inc. reported a net loss of $18.6 million for the fiscal year ended Dec 31, 2025, and used $16.4 million of cash in operations, per its annual report to the SEC.

How much does FibroBiologics spend on research and development?

$7.4 million in the fiscal year ended Dec 31, 2025, per its annual report.

## Investor discussion: FibroBiologics

Members talk about FibroBiologics (FBLG). Reader posts, not aibio.space reporting, and not investment advice.

Rules

1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
2. **Say whether you hold the stock.** Every post states long, short or no position.
3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you.
4. **No buy or sell calls and no price targets.**
5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them.
6. **No personal details and no spam.** No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion).

## Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at FibroBiologics, newest first. Each line links the filing it comes from.

1. 2026-09-18 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.07,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526395511/fblg-ex99_1.htm)
2. 2026-07-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/fblg-20260722.htm)
3. 2026-07-10 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526299884/fblg-20260709.htm)
4. 2026-06-29 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526288468/fblg-ex99_1.htm)
5. 2026-05-01 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526201376/fblg-20260501.htm)
6. 2026-04-20 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526164018/fblg-ex99_1.htm)
7. 2026-04-03 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526142089/fblg-20260330.htm)
8. 2026-03-27 Financings Reported a financing. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1958777/000149315226013274/forms-1.htm)
9. 2026-02-23 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526064040/fblg-20260220.htm)
10. 2026-02-06 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526041187/fblg-20260203.htm)
11. 2026-01-02 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312526001077/fblg-20251230.htm)
12. 2025-12-29 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312525332248/definitive_proxy_decembe.htm)
13. 2025-12-18 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312525323667/fblg-20251218.htm)
14. 2025-12-15 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1958777/000119312525319435/prosup_hcw_12.15.25.htm)
15. 2025-08-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000095017025105807/fblg-20250725.htm)
16. 2025-07-18 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000095017025096914/fblg-20250620.htm)
17. 2025-07-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000095017025093832/fblg-20250701.htm)
18. 2025-06-16 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000164117225015282/ex99-1.htm)
19. 2025-02-07 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000149315225005456/form8-k.htm)
20. 2025-01-14 Financings Filed a final prospectus for a securities offering. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1958777/000149315225002162/form424b4.htm)
21. 2024-12-31 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,5.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1958777/000149315224052707/ex99-1.htm)

## Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:FBLG on TradingView](https://www.tradingview.com/symbols/NASDAQ-FBLG/).

## SEC filings and registration

- **SEC name**: FibroBiologics, Inc.

- **CIK**: 1958777

- **Industry (SIC)**: Pharmaceutical Preparations (2834)

- **US tickers**: FBLG (Nasdaq)

- **State or country of incorporation**: DE

- **Fiscal year ends**: December 31

- **Filer category**: <br>Emerging growth company

- **Business address**: 9350 KIRBY DRIVE, HOUSTON, TX, 77054

- **Phone**: 281-671-5150

- **Shares outstanding**: 6,658,193 as of 2026-07-31 (10-Q filed 2026-07-31)

- **Former names**: FibroBiologics Inc.

### Recent filings (8-K and 6-K are the company's own announcements)

- [8-K](https://www.sec.gov/Archives/edgar/data/1958777/000119312526418065/fblg-20261007.htm) filed 2026-10-08
- [8-K](https://www.sec.gov/Archives/edgar/data/1958777/000119312526395511/fblg-20260917.htm) filed 2026-09-18
- [8-K](https://www.sec.gov/Archives/edgar/data/1958777/000119312526391310/fblg-20260915.htm) filed 2026-09-15
- [8-K](https://www.sec.gov/Archives/edgar/data/1958777/000119312526362027/fblg-20260820.htm) filed 2026-08-24
- [10-Q](https://www.sec.gov/Archives/edgar/data/1958777/000119312526328454/fblg-20260630.htm) filed 2026-07-31
- [DEF 14A](https://www.sec.gov/Archives/edgar/data/1958777/000119312526326818/fblg-20260731.htm) filed 2026-07-31
- [8-K](https://www.sec.gov/Archives/edgar/data/1958777/000119312526316067/fblg-20260722.htm) filed 2026-07-24
- [S-3](https://www.sec.gov/Archives/edgar/data/1958777/000119312526299884/fblg-20260709.htm) filed 2026-07-10

Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001958777), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

## Listing details

FibroBiologics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker FBLG, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

- **Company**: FibroBiologics, Inc.

- **Ticker**: FBLG

- **Listing**: NASDAQ

- **Country or territory**: United States

- **Business scope**: Biotechnology

- **ISIN**: US31573L2043

- **Last quote in directory**: 2026-10-21

- **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-FBLG/)

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/).

Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/).

Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update)

---
Source page: https://aibio.space/companies/fibrobiologics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "FibroBiologics (FBLG) news: reverse split and delisting", 2026-10-31, https://aibio.space/companies/fibrobiologics/